Mr. Speaker, again I do not want to defend either side of the argument. I supported the motion presented in the House that we not proceed with the bill at this current time based on the evidence that was provided. I understood that this type of labelling would not be effective as a stand-alone measure.
On the question of other labelling for other purposes, there are rules and regulations under the Food and Drugs Act that allergens have to be reported on and labelled. While I have not researched this matter, I presume that would be to what the member has referred.
Many people spoke on the question of labelling at committee. This is particularly true when it comes to questions like FASD and other problems associated with the abuse of alcohol. We have to reach the individuals at risk before they buy the bottle because often that decision will not change at that time.
For women of child-bearing age, who are considering pregnancy, it is important they have that understanding in the information and education provided to them prior to them buying a bottle. We heard the evidence of experts that it was too later for people who had problems, those who we refer commonly to as alcoholics, or women who continued to drink through pregnancy because of an alcohol or drug dependence. We have to work with them before it becomes a problem.
Those are elements that were provided by experts who appeared at committee on the strategy on comprehensive drug use. In this motion we talk about FASD. However, let us remember we heard at committee, and it was brought to light by the private member's bill, that there was more than the risk of FASD from the abuse of alcohol. There are general health risks such as liver disease, heart disease and cancer. There is also the risk in operating machinery while intoxicated or drinking and driving. Mothers Against Drunk Driving made an excellent presentation on those risks and costs to society and families due to alcohol abuse. Many of us know first-hand of the excesses of alcohol and the stress it can put on the family, the community, individuals and all our systems.
When I consider a comprehensive drug strategy, I go beyond FASD. This motion deals with FASD which is a very important element within that strategy.